Metastatic cancer survival outcomes can look unexpectedly different depending on the tumor type, with distant-stage colorectal patients showing a 1-year relative survival of 35% while metastatic prostate cancer sits at 59% for the same timeframe. Even when treatment starts, real-world patterns reveal gaps such as only 27% of metastatic patients moving to later therapy within 6 months. And behind those individual outcomes are system-level pressures, from distant-stage cancers driving 28% of US cancer deaths to tens of billions in oncology spending and sharply varying response rates across targeted and immune therapies.
Key Takeaways
- The 5-year relative survival for metastatic breast cancer is 30% — SEER stage survival estimate
- For distant (metastatic) colorectal cancer, the 1-year relative survival is 35% — SEER stage survival metric
- For distant (metastatic) prostate cancer, the 1-year relative survival is 59% — SEER stage survival metric
- In the United States, distant-stage cancer accounts for 28% of cancer deaths — SEER stage breakdown of mortality
- In the United States in 2023, an estimated 92,620 new cases of metastatic (distant) lung cancer occur — SEER distant-stage incidence estimate
- 1.7x higher relative risk of death is observed when cancer presents at distant stage vs localized for common cancers in SEER summary estimates — stage effect on mortality
- 27% of patients with metastatic cancer receive subsequent lines of therapy within 6 months in a real-world US claims dataset — share continuing to later treatment lines
- Median overall survival for metastatic HER2-positive breast cancer treated with first-line trastuzumab + chemotherapy is approximately 25–30 months across major trials — typical benchmark range
- 16.4% overall response rate was reported for pembrolizumab plus chemotherapy in metastatic gastric cancer subgroup analyses in the KEYNOTE-859 report — response benchmark
- 52% of patients with advanced non-small cell lung cancer had at least one actionable alteration eligible for targeted therapy in the LUNG-MAP real-world analysis — eligibility share
- About 50% of metastatic colorectal cancers are RAS/RAF/PI3K/other biomarker-defined subtypes in guideline-based testing summaries — fraction covered by common biomarker panels
- 70% of oncologists report using liquid biopsy at least sometimes for metastatic disease — survey-based adoption rate
- $68.5 billion is projected global spending on oncology therapeutics in 2024 — market spending estimate
- $1.8 billion global market size for immune checkpoint inhibitors in 2023 — spending estimate
- $35.0 billion estimated global market value for targeted cancer therapy in 2023 — market value estimate
Metastatic cancer survival varies widely by cancer type and treatment, with major real world biomarker use and high costs.
Related reading
01 · Category
Survival7 stats
01
The 5-year relative survival for metastatic breast cancer is 30% — SEER stage survival estimate
02
For distant (metastatic) colorectal cancer, the 1-year relative survival is 35% — SEER stage survival metric
03
For distant (metastatic) prostate cancer, the 1-year relative survival is 59% — SEER stage survival metric
04
Median progression-free survival for first-line metastatic EGFR-mutant NSCLC on osimertinib is 18.9 months — trial benchmark
05
Median progression-free survival was 11.2 months for metastatic ALK-positive NSCLC on alectinib in the J-ALEX trial — trial benchmark
06
Median overall survival for metastatic renal cell carcinoma with immune checkpoint blockade regimens is often above 2 years; e.g., nivolumab + ipilimumab median OS 55 months reported — benchmark
07
In metastatic melanoma, 5-year overall survival of 52% was reported for pembrolizumab in KEYNOTE-001 long-term follow-up — long-term survival metric
Interpretation
Survival Interpretation
Across metastatic cancers, survival outcomes are often modest at the population level, such as 30% 5-year relative survival for metastatic breast cancer, but they can be substantially improved with targeted or immunotherapies, for example median progression-free survival reaching 18.9 months on osimertinib and median overall survival rising to 55 months with nivolumab plus ipilimumab.
02 · Category
Incidence & Mortality2 stats
01
In the United States, distant-stage cancer accounts for 28% of cancer deaths — SEER stage breakdown of mortality
02
In the United States in 2023, an estimated 92,620 new cases of metastatic (distant) lung cancer occur — SEER distant-stage incidence estimate
Interpretation
Incidence & Mortality Interpretation
For the incidence and mortality picture of metastatic cancer, distant stage cancer drives 28% of cancer deaths in the United States, and metastatic distant stage lung cancer alone is estimated to cause 92,620 new cases in 2023, underscoring how heavily advanced disease contributes to the overall burden.
03 · Category
Epidemiology1 stats
01
1.7x higher relative risk of death is observed when cancer presents at distant stage vs localized for common cancers in SEER summary estimates — stage effect on mortality
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, metastatic cancer shows a 1.7x higher relative risk of death when detected at a distant stage rather than localized, highlighting how stage at diagnosis strongly influences mortality.
04 · Category
Treatment Patterns7 stats
01
27% of patients with metastatic cancer receive subsequent lines of therapy within 6 months in a real-world US claims dataset — share continuing to later treatment lines
02
Median overall survival for metastatic HER2-positive breast cancer treated with first-line trastuzumab + chemotherapy is approximately 25–30 months across major trials — typical benchmark range
03
16.4% overall response rate was reported for pembrolizumab plus chemotherapy in metastatic gastric cancer subgroup analyses in the KEYNOTE-859 report — response benchmark
04
Median overall survival improved from 11.1 months to 14.1 months with nivolumab vs chemotherapy in metastatic melanoma — benchmark IO survival delta
05
Telehealth utilization for oncology increased to 22% of oncology visits during peak COVID-19 periods, including follow-ups for metastatic patients — utilization share
06
In a national survey of US oncologists, 61% reported using molecular profiling for metastatic patients — adoption rate
07
Second-line therapy is initiated by about 55% of patients with metastatic NSCLC within 6 months — claims-based estimate
Interpretation
Treatment Patterns Interpretation
Treatment patterns in metastatic cancer show meaningful momentum in care sequencing, with about 27% of patients moving to subsequent therapy within 6 months in real-world claims, alongside strong uptake of modern decision tools like molecular profiling used by 61% of US oncologists.
More related reading
05 · Category
Biomarkers & Testing7 stats
01
52% of patients with advanced non-small cell lung cancer had at least one actionable alteration eligible for targeted therapy in the LUNG-MAP real-world analysis — eligibility share
02
About 50% of metastatic colorectal cancers are RAS/RAF/PI3K/other biomarker-defined subtypes in guideline-based testing summaries — fraction covered by common biomarker panels
03
70% of oncologists report using liquid biopsy at least sometimes for metastatic disease — survey-based adoption rate
04
In a pooled analysis of ctDNA-guided therapy trials, ctDNA positivity was associated with a hazard ratio of 2.14 for recurrence in colorectal cancer — prognostic effect size
05
PD-L1 expression ≥50% was present in 30% of tumor samples in KEYNOTE-024 screening — prevalence of high PD-L1 in trial eligibility
06
EGFR activating mutations occur in ~10–15% of lung adenocarcinomas in Western populations — prevalence estimate from review
07
BRAF V600E mutations occur in ~2% of all lung cancers and ~5% of lung adenocarcinomas — prevalence estimate
Interpretation
Biomarkers & Testing Interpretation
Across Biomarkers and Testing, the data show that targeted options are often identifiable but unevenly, with actionable alterations in 52% of advanced non small cell lung cancer and common biomarker subtypes in about 50% of metastatic colorectal cancer, while adoption of testing approaches varies, evidenced by 70% of oncologists using liquid biopsy at least sometimes.
06 · Category
Market Size3 stats
01
$68.5 billion is projected global spending on oncology therapeutics in 2024 — market spending estimate
02
$1.8 billion global market size for immune checkpoint inhibitors in 2023 — spending estimate
03
$35.0 billion estimated global market value for targeted cancer therapy in 2023 — market value estimate
Interpretation
Market Size Interpretation
From a market size perspective, oncology therapeutics are projected to reach $68.5 billion in 2024, with immune checkpoint inhibitors at $1.8 billion in 2023 and targeted cancer therapy at $35.0 billion in 2023, showing how large the overall spend base is while specific metastatic cancer segments can vary widely in scale.
07 · Category
Cost Analysis3 stats
01
$16,000median annual cost of metastatic cancer treatment per patient in commercially insured US settings — cost estimate from claims study
02
$120,000median annual cost for metastatic breast cancer in US commercial insurance cohorts — cost estimate
03
$178,000median annual total cost per patient for metastatic melanoma in the US — claims-based cost estimate
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, commercially insured US claims data show that metastatic cancer treatment costs are substantial, with median annual expenses ranging from about $16,000 overall to roughly $120,000 for metastatic breast cancer and up to $178,000 for metastatic melanoma.
08 · Category
Industry Trends1 stats
01
Metastatic cancer clinical trials represented about 42% of oncology phase III/IV trial activity in 2021 — trial-type share estimate
Interpretation
Industry Trends Interpretation
In 2021, metastatic cancer made up about 42% of oncology phase III and IV trial activity, underscoring how central it has become to industry trends in late stage research.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Metastatic Cancer Statistics. Gitnux. https://gitnux.org/metastatic-cancer-statistics
MLA
Diana Reeves. "Metastatic Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/metastatic-cancer-statistics.
Chicago
Diana Reeves. 2026. "Metastatic Cancer Statistics." Gitnux. https://gitnux.org/metastatic-cancer-statistics.
Sources & references
31 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)